{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:57:33Z","timestamp":1790449053414,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,30]],"date-time":"2027-06-30T00:00:00Z","timestamp":1814313600000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K76AG083287"],"award-info":[{"award-number":["K76AG083287"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jpainsymman.2026.03.010","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:26:32Z","timestamp":1774110392000},"page":"e73-e79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second-Generation Antipsychotics for Depression in Serious Illness: A First-Line Augmentation Strategy"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-7368","authenticated-orcid":false,"given":"Gregg","family":"Robbins-Welty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4724-1519","authenticated-orcid":false,"given":"Mia","family":"Pattillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6219-7619","authenticated-orcid":false,"given":"Danielle","family":"Chammas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Sadowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2921-1421","authenticated-orcid":false,"given":"Cara L.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-9374","authenticated-orcid":false,"given":"Nneka","family":"Ufere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-9499","authenticated-orcid":false,"given":"Jason A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8168-2255","authenticated-orcid":false,"given":"Daniel","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0001","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4103\/0019-5545.58304","article-title":"The story of antipsychotics: past and present","volume":"51","author":"Ramachandraiah","year":"2009","journal-title":"Indian J Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000061657","article-title":"Augmentation strategies for treatment of unipolar major depression","volume":"25","author":"Nelson","year":"1997","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70166","article-title":"Efficacy and safety of pharmacotherapy for cancer cachexia: a systematic review and network meta-analysis","volume":"13","author":"Chen","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0004","doi-asserted-by":"crossref","unstructured":"Kishimoto T, Hagi K, Kurokawa S, et al. Efficacy and safety\/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med;53:4064\u20134082.","DOI":"10.1017\/S0033291722000745"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0005","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1586\/14737175.2013.846520","article-title":"The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder","volume":"13","author":"Weisler","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0006","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/01.jcp.0000130557.08996.7a","article-title":"A double-blind, randomized study of olanzapine and olanzapine\/fluoxetine combination for major depression with psychotic features","volume":"24","author":"Rothschild","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2010.06.031","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study","volume":"128","author":"Bortnick","year":"2011","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/a-1934-9856","article-title":"Antipsychotic monotherapy for major depressive disorder: a systematic review and meta-analysis","volume":"56","author":"Nishi","year":"2023","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0009","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7326\/M22-1845","article-title":"Nonpharmacologic and pharmacologic treatments of adult patients with major depressive disorder: a systematic review and network meta-analysis for a clinical guideline by the American College of Physicians","volume":"176","author":"Gartlehner","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0010","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1017\/S0033291722001246","article-title":"Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis","volume":"52","author":"Yan","year":"2022","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0011","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jpainsymman.2026.03.010_bib0012","first-page":"11","article-title":"Quetiapine monotherapy for bipolar depression","volume":"4","author":"Thase","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0013","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0014","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appelberg","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40263-014-0152-8","article-title":"Role of lithium augmentation in the management of major depressive disorder","volume":"28","author":"Bauer","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0017","first-page":"323","article-title":"Management of major depression: guidelines from the VA\/DoD","volume":"107","author":"Buelt","year":"2023","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0018","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0020","unstructured":"SEROQUEL XR- quetiapine tablet, extended release DRUG LABEL. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=473a3ac4-67f4-4782-baa9-7f9bdd8761f4. Accessed March 18, 2025."},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0021","unstructured":"ABILIFY- aripiprazole tablet - DRUG LABEL. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f9648990-0627-4c66-aae1-d3eef398b5b4. Accessed March 18, 2025."},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0022","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamapsychiatry.2015.3447","article-title":"Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial","volume":"73","author":"Kaneriya","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0023","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","article-title":"Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0024","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1345\/aph.1P397","article-title":"Use of risperidone as augmentation treatment for major depressive disorder","volume":"45","author":"Owenby","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0025","unstructured":"ZYPREXA- olanzapine tablet ZYPREXA ZYDIS- olanzapine tablet, orally disintegrating ZYPREXA INTRAMUSCULAR- olanzapine injection, powder, for solution -DRUG LABEL. Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341. Accessed March 18, 2025."},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1440-1819.2010.02184.x","article-title":"Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: consecutive case series","volume":"65","author":"Nozawa","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hup.914","article-title":"Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series","volume":"23","author":"Takahashi","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0028","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/026988110401800303","article-title":"Receptor mechanisms in the treatment of schizophrenia","volume":"18","author":"Reynolds","year":"2004","journal-title":"J Psychopharmacol"},{"issue":"Suppl 19","key":"10.1016\/j.jpainsymman.2026.03.010_bib0029","first-page":"6","article-title":"The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0030","first-page":"268","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim Care Compan J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0031","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2204462","article-title":"Antidepressant augmentation versus switch in treatment-resistant geriatric depression","volume":"388","author":"Lenze","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0032","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. The Cochrane database of systematic reviews Cochrane","volume":"9","author":"Sutherland","year":"2018","journal-title":"Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0033","first-page":"3439","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature","volume":"29","author":"Chow","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0034","first-page":"5831","article-title":"Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study","volume":"29","author":"Maeda","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115437","article-title":"Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study): a phase III crossover trial","volume":"222","author":"Zhang","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0036","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/15360288.2025.2492801","article-title":"Comparison of effectivity and safety of Olanzapine and Mirtazapine on cancer-associated anorexia and cachexia in advanced oral cavity cancer patients: prospective, comparative, interventional study","volume":"39","author":"Singhal","year":"2025","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0037","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24f15532","article-title":"Therapeutic effects, side effects, and adverse effects of neuropsychiatric drugs in the context of treating cancer-related anorexia with olanzapine and mirtazapine","volume":"85","author":"Andrade","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0038","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of Olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0039","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00228-024-03770-x","article-title":"Effects of olanzapine in the improvement of body weight and appetite in patients with cancer or receiving chemotherapy: a systematic review and meta-analysis","volume":"81","author":"Yuan","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0040","first-page":"2649","article-title":"Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines","volume":"23","author":"Naing","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257129","article-title":"Antipsychotic-induced extrapyramidal side effects: a systematic review and meta-analysis of observational studies","volume":"16","author":"Ali","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0042","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0043","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40263-021-00859-0","article-title":"Antipsychotic-induced constipation: a review of the pathogenesis, clinical diagnosis, and treatment","volume":"35","author":"Xu","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0044","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaclp.2022.09.006","article-title":"Antipsychotic safety in liver disease: a narrative review and practical guide for the clinician","volume":"64","author":"Gunther","year":"2023","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0046","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00228-024-03714-5","article-title":"Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis","volume":"80","author":"Ong","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-038247","article-title":"Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study","volume":"10","author":"H\u00f8jlund","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpainsymman.2026.03.010_bib0048","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaclp.2024.12.001","article-title":"Palliative electroconvulsive therapy: a descriptive cohort study","volume":"66","author":"Robbins-Welty","year":"2025","journal-title":"J Acad Consult Liaison Psychiatry"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392426001016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392426001016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:33:42Z","timestamp":1783204422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392426001016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0885392426001016"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2026.03.010","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Generation Antipsychotics for Depression in Serious Illness: A First-Line Augmentation Strategy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2026.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}